PCI Biotech starts dosing in Phase I extension study for bile duct cancer
Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 14, 2017 Category: Pharmaceuticals Source Type: news
Chiasma and FDA agree on new Phase III trial design for acromegaly drug
The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma ’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acrome… (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2017 Category: Pharmaceuticals Source Type: news
Viamet reports positive Phase II data for vulvovaginal candidiasis drug
Viamet Pharmaceuticals has reported positive results from a Phase II clinical trial (REVIVE) of VT-1161 to treat recurrent vulvovaginal candidiasis (RVVC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2017 Category: Pharmaceuticals Source Type: news
Cyclodextrin slows NPC progression in new Washington University trial
A new clinical trial conducted by Washington University School of Medicine in St Louis and the National Institutes of Health (NIH) in the US has shown that a drug called cyclodextrin slows progression of Niemann-Pick type C (NPC) disease. (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2017 Category: Pharmaceuticals Source Type: news
Immunicum starts enrolment in US for Phase II oncology trial
Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news
UK researchers report positive data from new diabetes trial
Researchers from King ’s College London and Cardiff University in the UK have reported positive results from the new MonoPepT1De clinical trial using immunotherapy for type 1 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news
Biotecnol and Cancer Research UK to assess Tb535H for solid tumours
Immune-oncology firm Biotecnol and Cancer Research UK have entered a collaboration agreement to evaluate Tb535H in clinical trials to treat patients suffering from solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: SELLAS Life Sciences Group, Cempra
SELLAS Life Sciences Group has signed a definitive agreement to merge with Galena Biopharma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics
HitGen has signed an agreement with LEO Pharma to use its advanced technology platform to discover new small molecules. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news
Allegro ’s Phase IIb stage 2 trial for DME drug meets primary endpoint
Biotechnology firm Allegro Ophthalmics has reported positive top-line results from the DEL MAR Phase IIb stage 2 clinical trial of luminate as a sequential therapy to treat diabetic macular edema (DME) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
TapImmune broadens TPIV200 ’s Phase II trial for ovarian cancer
US-based immuno-oncology firm TapImmune has amended the Phase II clinical trial of its therapeutic peptide vaccine TPIV200 following discussions with the US Food and Drug Administration (FDA). (Source: Drug Development Technology)
Source: Drug Development Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
WIN Consortium to conduct targeted tri-therapy trial for NSCLC
French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC), following appro … (Source: Drug Development Technology)
Source: Drug Development Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
MAVYRET ™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C
MAVYRET ™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6). (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news
Zynerba ’s Phase II epilepsy trial of ZYN002 fails to meet primary endpoint
Zynerba Pharmaceuticals has reported top-line results from the Phase II STAR 1 clinical trial of ZYN002 to treat adult epilepsy patients with focal seizures. (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news
Amylyx begins dosing in Phase II trial of AMX0035 for ALS
Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news
